UK raids seize nearly 2,000 doses labeled as tirzepatide and retatrutide

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) announced raids on Feb. 25 in Lincolnshire and Nottinghamshire that seized almost 2,000 doses of illegal weight-loss drugs, along with manufacturing equipment, packaging materials, and commercial vehicles ^[1]. The seized products were labeled as containing tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound, and retatrutide, an experimental obesity drug still in clinical trials that is not approved for use anywhere ^[1].

This is the MHRA's second major enforcement action against illegal weight-loss drug manufacturing in four months ^[1]. In October 2025, the agency dismantled what it called the world's largest illicit weight-loss medicine manufacturing facility, located in central England ^[1][2]. That raid netted 2,000 injection pens labeled as tirzepatide, additional products labeled as retatrutide, tens of thousands of empty pens, and raw chemicals [2]. UK health minister Wes Streeting called the October operation "a victory in the fight against the shameless criminals who are putting lives at risk by peddling dangerous and illegal weight-loss jabs to make a quick buck" [2].

Reuters reported that the crackdown reflects escalating enforcement against illegal manufacturers exploiting surging global demand for weight-loss treatments, as regulators and drug companies work to counter counterfeit and unregulated products sold online and through underground networks ^[1]. In Britain, the National Health Service prescribes weight-loss medicines only to patients who meet specific clinical criteria, and those seeking private prescriptions can pay hundreds of pounds a month, conditions that PharmExec's reporting links to demand shifting toward counterfeit and unregulated channels [2].

Why it matters for patients

These raids happened in the UK, not the United States, but they point to a problem that crosses borders: counterfeit and unregulated versions of popular weight-loss drugs are circulating as demand outpaces supply and official prices remain high ^[1][2]. Products labeled as retatrutide are especially notable because that drug is investigational and not approved anywhere, meaning any product sold under that name outside a clinical trial has not gone through safety or quality review by any regulator ^[1]. Products seized in the October raid also included raw chemicals and unlabeled pens, which the MHRA said posed a major risk to unwitting customers because they were made "with no regard for safety or quality" [2].

The sources do not say whether any of the seized products reached patients or caused harm, so the actual health impact of this specific haul is not yet known. But the pattern, two large seizures within four months in a country with a national health system, illustrates how criminal networks are producing fake versions of both approved drugs like tirzepatide and unapproved ones like retatrutide, then labeling them to look legitimate ^[1][2]. For US readers, the parallel is that FDA Commissioner Marty Makary has said the agency expects to take action against copycat GLP-1 products marketed as alternatives to approved therapies, which the source describes as part of a broader regulatory push against unapproved products sold at scale ^[1].

What happens next

The MHRA has not announced additional details about prosecutions or further seizures tied to the Feb. 25 raids ^[1]. In the US, the sources indicate the FDA is expected to move against copycat GLP-1 marketing, though no specific date or action has been confirmed in the available reporting ^[1]. Whether coordinated enforcement between UK and US regulators expands is not addressed in these sources.